Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Willems, Stefan M ^a   Schrage, Yvonne M ^a   Bruijn, Inge H B ^a   Szuhai, Karoly ^a   Hogendoorn, Pancras C W ^a   Bovée, Judith V M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4,5,6,7 TETRABROMOBENZOTRIAZOLE; CASEIN KINASE II; CASPASE 3; DASATINIB; ENZYME INHIBITOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KINOME; PROTEIN FUS; PROTEIN KINASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; 4,5,6,7-TETRABROMOBENZOTRIAZOLE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MYXOSARCOMA; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; CELL CULTURE; CELL LINE; CELL SURVIVAL; ENZYMOLOGY; GENETICS; HELA CELL; IMMUNOBLOTTING; KARYOTYPING; LEUKEMIA CELL LINE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

CASEIN KINASE II; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; HELA CELLS; HUMANS; IMMUNOBLOTTING; JURKAT CELLS; KARYOTYPING; LIPOSARCOMA, MYXOID; NF-KAPPA B; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES; TRIAZOLES;

EID: 77956877001     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-257     Document Type: Article

References (59)

1. Antonescu C, Ladanyi M. Myxoid liposarcoma. World Health Organization classification of tumours. pathology and genetics. Tumours of soft tissue and bone 2004, 40-43. Lyon: IARC press, Fletcher CDM, Unni KK, Mertens F, 2002.
2. Willems SM, Wiweger M, Graadt van Roggen JF, Hogendoorn PCW. Running GAGs: myxoid matrix in tumor pathology revisited: What's in it for the pathologist?. Virchows Arch 2010, 456:181-192. 10.1007/s00428-009-0822-y, 2828560, 19705152.
3. Turc-Carel C, Limon J, Dal Cin P, Rao U, Karakousis C, Sandberg AA. Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet 1986, 23:291-299. 10.1016/0165-4608(86)90011-7, 3779625.
4. Panagopoulos I, Hoglund M, Mertens F, Mandahl N, Mitelman F, Aman P. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996, 12:489-494.
5. Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, Bridge JA, Neff JR, Goldblum JR, Ladanyi M. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 2001, 7:3977-3987.
6. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le CA, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007, 8:595-602. 10.1016/S1470-2045(07)70175-4, 17586092.
7. Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Pilotti S, Casali PG. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009, 20:1439-1444. 10.1093/annonc/mdp004, 19465423.
8. Dalal KM, Antonescu CR, Singer S. Diagnosis and management of lipomatous tumors. J Surg Oncol 2008, 97:298-313. 10.1002/jso.20975, 18286473.
9. Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, Larsen AK. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 2007, 104:13062-13067. 10.1073/pnas.0609877104, 1941813, 17656556.
10. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996, 35:13303-13309. 10.1021/bi960306b, 8873596.
11. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999, 42:2493-2497. 10.1021/jm990241l, 10411470.
12. Theman TA, Hartzell TL, Sinha I, Polson K, Morgan J, Demetri GD, Orgill DP, George S. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol 2009, 27:e198-e200. 10.1200/JCO.2008.21.6473, 19805684.
13. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gomez J, Park YC, Le Cesne A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009, 27:4188-4196. 10.1200/JCO.2008.21.0088, 19652065.
14. Tuveson DA, Fletcher JA. Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol 2001, 13:249-255. 10.1097/00001622-200107000-00007, 11429482.
15. Widakowich C, de CG, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007, 12:1443-1455. 10.1634/theoncologist.12-12-1443, 18165622.
16. Schrage YM, Briaire-de Bruijn IH, de Miranda NF, van Oosterwijk J, Taminiau AHM, van Wezel T, Hogendoorn PCW, Bovee JVMG. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009, 69:6216-6222. 10.1158/0008-5472.CAN-08-4801, 19602594.
17. Goransson M, Elias E, Stahlberg A, Olofsson A, Andersson C, Aman P. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. Int J Cancer 2005, 115:556-560. 10.1002/ijc.20893, 15688424.
18. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell TJ, Cibulskis K, Onofrio RC, Saito T, Shukla N, Lau C, Nelander S, Silver SJ, Sougnez C, Viale A, Winckler W, Maki RG, Garraway LA, Lash A, Greulich H, Root DE, Sellers WR, Schwartz GK, Antonescu CR, Lander ES, Varmus HE, Ladanyi M, Sander C, Meyerson M, Singer S. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010, 42:715-721. 10.1038/ng.619, 20601955.
19. Goransson M, Andersson MK, Forni C, Stahlberg A, Andersson C, Olofsson A, Mantovani R, Aman P. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene 2009, 28:270-278. 10.1038/onc.2008.378, 18850010.
20. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. 10.1038/nature04870, 16724054.
21. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002, 2:664-674. 10.1038/nri887, 2668257, 12209135.
22. Panagopoulos I, Mertens F, Isaksson M, Mandahl N. A novel FUS/CHOP chimera in myxoid liposarcoma. Biochem Biophys Res Commun 2000, 279:838-845. 10.1006/bbrc.2000.4026, 11162437.
23. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, Shugar D, Pinna LA. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett 2001, 496:44-48. 10.1016/S0014-5793(01)02404-8, 11343704.
24. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009, 66:1858-1867. 10.1007/s00018-009-9154-y, 19387548.
25. Grant SK. Therapeutic protein kinase inhibitors. Cell Mol Life Sci 2009, 66:1163-1177. 10.1007/s00018-008-8539-7, 19011754.
26. Perez-Mancera PA, Bermejo-Rodriguez C, Sanchez-Martin M, Abollo-Jimenez F, Pintado B, Sanchez-Garcia I. FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. PLoS One 2008, 3:e2569. 10.1371/journal.pone.0002569, 2434200, 18596980.
27. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289-312. 10.1146/annurev.biochem.77.061307.091829, 18518822.
28. Willems SM, van RA, van ZR, Deelder AM, McDonnell LA, Hogendoorn PC. Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity. J Pathol 2010,
29. Crozat A, Aman P, Mandahl P, Ron D. Fusion of CHOP a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993, 363:640-644. 10.1038/363640a0, 8510758.
30. Kuroda M, Ishida T, Takanashi M, Satoh M, Machinami R, Watanabe T. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 1997, 151:735-744. 1857848, 9284822.
31. Riggi N, Cironi L, Provero P, Suva ML, Stehle JC, Baumer K, Guillou L, Stamenkovic I. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006, 66:7016-7023. 10.1158/0008-5472.CAN-05-3979, 16849546.
32. Engstrom K, Willen H, Kabjorn-Gustafsson C, Andersson C, Olsson M, Goransson M, Jarnum S, Olofsson A, Warnhammar E, Aman P. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol 2006, 168:1642-1653. 10.2353/ajpath.2006.050872, 1606602, 16651630.
33. Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999, 96:3951-3956. 10.1073/pnas.96.7.3951, 22401, 10097144.
34. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003, 89:1409-1412. 10.1038/sj.bjc.6601306, 2394353, 14562008.
35. Huang HY, Antonescu CR. Molecular variability of TLS-CHOP structure shows no significant impact on the level of adipogenesis: a comparative ultrastructural and RT-PCR analysis of 14 cases of myxoid/round cell liposarcomas. Ultrastruct Pathol 2003, 27:217-226. 10.1080/01913120309917, 12907366.
36. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62. 10.1038/nrm2083, 17183360.
37. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 2002, 62:6770-6778.
38. Schwarzbach MH, Koesters R, Germann A, Mechtersheimer G, Geisbill J, Winkler S, Niedergethmann M, Ridder R, Buechler MW, von Knebel DM, Willeke F. Comparable transforming capacities and differential gene expression patterns of variant FUS/CHOP fusion transcripts derived from soft tissue liposarcomas. Oncogene 2004, 23:6798-6805. 10.1038/sj.onc.1207840, 15286712.
39. Uranishi H, Tetsuka T, Yamashita M, Asamitsu K, Shimizu M, Itoh M, Okamoto T. Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J Biol Chem 2001, 276:13395-13401. 10.1074/jbc.M011176200, 11278855.
40. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 1997, 94:2927-2932. 10.1073/pnas.94.7.2927, 20299, 9096323.
41. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 1997, 275:523-527. 10.1126/science.275.5299.523, 8999795.
42. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998, 12:968-981. 10.1101/gad.12.7.968, 316671, 9531535.
43. Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 2008, 1784:33-47.
44. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004, 5:897-907. 10.1038/nrm1496, 15520809.
45. Hengartner MO. The biochemistry of apoptosis. Nature 2000, 407:770-776. 10.1038/35037710, 11048727.
46. Solares AM, Santana A, Baladron I, Valenzuela C, Gonzalez CA, Diaz A, Castillo D, Ramos T, Gomez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, Lopez-Saura P. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer 2009, 9:146. 10.1186/1471-2407-9-146, 2689241, 19439079.
47. Rudd CE, Trevillyan JM, Dasgupta JD, Wong LL, Schlossman SF. The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. Proc Natl Acad Sci USA 1988, 85:5190-5194. 10.1073/pnas.85.14.5190, 281714, 2455897.
48. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999, 21:187-190. 10.1038/5971, 9988270.
49. Cheng H, Dodge J, Mehl E, Liu S, Poulin N, van de RM, Nielsen TO. Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Hum Pathol 2009, 40:1244-1251. 10.1016/j.humpath.2009.01.011, 19368956.
50. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009, 69:3842-3849. 10.1158/0008-5472.CAN-08-2246, 2709758, 19383922.
51. Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA, Kung AL, Golub TR. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 2009, 27:77-83. 10.1038/nbt.1513, 19098899.
52. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681. 10.1124/pr.58.3.10, 16968952.
53. Thelin-Jarnum S, Lassen C, Panagopoulos I, Mandahl N, Aman P. Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas. Int J Cancer 1999, 83:30-33. 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4, 10449603.
54. Aman P, Ron D, Mandahl N, Fioretos T, Heim S, Arheden K, Willen H, Rydholm A, Mitelman F. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 1992, 5:278-285. 10.1002/gcc.2870050403, 1283316.
55. Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PCW, Sciot R. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 2006, 19:407-416. 10.1038/modpathol.3800550, 16415793.
56. Willems SM, Mohseny AB, Balog C, Sewrajsing R, Briaire-de Bruijn IH, Knijnenburg J, Cleton-Jansen AM, Sciot R, Fletcher CDM, Deelder AM, Szuhai K, Hensbergen PJ, Hogendoorn PCW. Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med 2009, 13:1291-1301. 10.1111/j.1582-4934.2009.00747.x, 19320777.
57. Szuhai K, Tanke HJ. COBRA: combined binary ratio labeling of nucleic-acid probes for multi-color fluorescence in situ hybridization karyotyping. Nat Protoc 2006, 1:264-275. 10.1038/nprot.2006.41, 17406243.
58. Willems SM, Schrage YM, Baelde JJ, Briaire-de Bruijn I, Mohseny A, Sciot R, Bovee JVMG, Hogendoorn PCW. Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition. Histopathology 2008, 52:465-474. 10.1111/j.1365-2559.2008.02967.x, 18315599.
59. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 2008, 68:1213-1220. 10.1158/0008-5472.CAN-07-5172, 18281498.